|
Baseline characteristics
|
HDA subgroup/original RCT (n/N)
|
| 134/273 | 131/275 | 171/290 | 156/287 | 292/451 | 135/226 | 248/556 | 108/280 |
| SELENA-SLEDAI score, mean (SD) | 10.3 (3.4) | 11.4 (4.1) | 10.8 (4.0) | 10.8 (3.7) | 10.4 (3.8) | 11.3 (4.0) | 11.5 (3.3) | 11.7 (3.1) |
|
SRI response at 52 weeks, %
| 45.5 | 28.2 | 56.1 | 34.6 | 54.0 | 34.1 | 64.6 | 47.2 |
|
Outcome at 52 weeks
|
Odds ratio SC/IV (95% credibility interval)
|
| HDA criteria | 1 | 2 |
| SRI response | 0.90 (0.53, 1.52) | 0.88 (0.58, 1.33) |
| 4-point reduction in SELENA-SLEDAI | 0.99 (0.58, 1.68) | 0.95 (0.63, 1.43) |
| Rate of severe flares | 0.69 (0.37, 1.28) | 0.89 (0.53, 1.50) |